Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities, has signed a letter of intent to be acquired by
Superlatus to be acquired by TRxADE HEALTH to create a global food consolidation platform
Categories
Health Care
Ocean Biomedical extends patent rights for idiopathic pulmonary fibrosis discovery to Europe
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Friday revealed that its scientific co-founder Dr. Jack Elias has received notice from the
Walgreens Boots Alliance (WBA) set to report Q3 results. What’s in the cards
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), a leading retailer and wholesaler of health and wellness products, is scheduled to report third-quarter earnings
Avid Bioservices Inc. (CDMO) Q4 2023 Earnings Call Transcript
Avid Bioservices Inc. (NASDAQ: CDMO) Q4 2023 earnings call dated Jun. 21, 2023 Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President and Chief
Patterson Companies, Inc. (PDCO) Q4 2023 Earnings Call Transcript
Patterson Companies, Inc. (NASDAQ: PDCO) Q4 2023 earnings call dated Jun. 21, 2023 Corporate Participants: John M. Wright -- Vice President of Investor Relations
Fundamental Research Corp. raises Ocean Biomedical’s price target to $17.63 per share
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Wednesday said that Fundamental Research Corp. increased the price target of the company’s stock to $17.63
Earnings Summary: A snapshot of Catalent’s Q3 2023 results
Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, has reported earnings for the third
Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific
Earnings Summary: CooperCompanies (COO) reports Q2 2023 financial results
Medical device maker CooperCompanies (NYSE: COO) has announced financial results for the second quarter of 2023, reporting lower earnings despite an increase
Taglich Brothers initiates coverage of Ocean Biomedical, with price target of $20
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday revealed that Taglich Brothers initiated coverage on the company with a share price
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharmaceutical company focused on clinical programs in oncology, fibrosis, infectious disease, and inflammation. Its business
Infographic: How Medtronic (MDT) performed in Q4 2023
Medtronic plc (NYSE: MDT) reported fourth quarter 2023 earnings results today. Revenue was $8.5 billion, up 5.6% year-over-year, both on a reported
Ocean Biomedical (OCEA) set to join the Russell 2000 Index
Biopharmaceutical company Ocean Biomedical (NASDAQ: OCEA) on Thursday said it is expected to be added to the Russell 2000 Index, effective after
Strides Pharma Science Limited (STAR) Q4 2023 Earnings Con Call Transcript
Strides Pharma Science Limited ( ?????? : STAR) Q4 2023 Earnings Con Call dated May. 25, 2023 Corporate participants: Arun Kumar --
Agilent Technologies (A) Q2 2023 earnings, revenue increase
Agilent Technologies (NYSE: A) has announced second-quarter 2023 financial results, reporting an increase in adjusted profit and revenues. The Santa Clara, California-based
Ocean Biomedical (OCEA) announces patent award for novel cancer immunotherapy treatment
Biopharma company Ocean Biomedical (NASDAQ: OCEA) on Tuesday said its scientific co-founder Dr. Jack Elias has been issued a broad patent for
Ocean Biomedical announces private placement of $25 mln convertible notes
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it has entered into a private placement pursuant to a securities purchase
Cara Therapeutics Inc (CARA) Q1 2023 Earnings Call Transcript
Cara Therapeutics Inc (NASDAQ: CARA) Q1 2023 earnings call dated May. 15, 2023 Corporate Participants: Matthew Murphy -- Manager of Investor Relations Christopher Posner -- Chief
TRxADE HEALTH Inc (MEDS) Q1 2023 Earnings Call Transcript
TRxADE HEALTH Inc (NASDAQ: MEDS) Q1 2023 earnings call dated May. 15, 2023 Corporate Participants: Prashant Patel -- Interim Chief Financial Officer Suren Ajjarapu -- Chairman and
MEDS Earnings: Trxade Health’s net loss narrows in Q1 2023; revenue down 31%
Trxade Health, Inc. (NASDAQ: MEDS), a leading health service IT company, reported a decrease in revenues for the first quarter of fiscal
Bio Path Holdings Inc (BPTH) Q1 2023 Earnings Call Transcript
Bio Path Holdings Inc (NASDAQ:BPTH) Q1 2023 Earnings Call dated May. 12, 2023. Corporate Participants: Will O'Connor -- Managing Director Peter H. Nielsen -- Chairman, President,